• Indications: Nerlynx® (neratinib) tablets, for oral use, is a kinase inhibitor indicated:

    • As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
    • In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.
  • Nerlynx is the first and only HER2-directed small molecule approved in both early-stage and metastatic HER2+ breast cancer1

    Nerlynx is a small molecule that demonstrates irreversible intracellular pan-HER signaling inhibition2